Pilot Study on Proteomics of Erythrocyte Proteins in Patients With COPD Based on TMT Technology

Chronic obstructive pulmonary disease (COPD), a common and complex disease characterized by persistent airflow limitation, is a leading cause of mortality worldwide. COPD and its comorbidity are associated with hypoxia condition. Further investigations on the cellular and molecular aspects of hypoxia in COPD should help to reveal the mechanisms underlying the development of this disease. Dysfunction of the erythrocyte, a main medium to transport oxygen through the blood, contributes to the prognosis and severity of COPD through hypoxia. It is proposed that dysregulated proteins in erythrocytes that impair oxygen transport may be involved in the development of COPD. However, a comprehensive study on altered proteins of erythrocytes in COPD is still lacking. Proteomics techniques and protein chip techniques provide a high throughput screening method to figure out characteristic inflammatory or metabolic markers of diseases. Therefore, this study is to evaluate the clinical significance of differential erythrocyte proteins in the course of COPD disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Protein; Disease Chronic Disease Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhujiang Hospital,Southern Medical Universtiy

Guangzhou, Guangdong, 510282, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

case group

Inclusion criteria

Age from 40 to 80 years old; gender is not limited.
Stable COPD
Sign the informed consent with the willingness of obeying the protocol. -

Exclusion criteria

Subjects with known other chronic respiratory diseases except for COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
Subjects had been accepted lung lobectomy or transplantation;
Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
Alcoholism, drug or solvents addition;
Acute exacerbation COPD patients (AECOPD) -
control group Inclusion criteria

Age from 40 to 80 years old; gender is not limited.
Sign the informed consent with the willingness of obeying the protocol. - Exclusion criteria

Subjects with known other chronic respiratory diseases (such as COPD, asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
Subjects had been accepted lung lobectomy or transplantation;
Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
Alcoholism, drug or solvents addition;

Treatment and study plan

No intervention

Other

no intervention

Primary outcomes

Protein biomarkers in erythrocyte predicting rapid decline of lung function

Time frame: 2021-7-15 to 2022-7-15

The study is to identify the biomarkers and make sure which is associated with rapid decline of lung function. The study will include a total of 30 study subjects.

Sponsors and collaborators

Lead sponsor

Zhujiang Hospital

Other

Registry information

Official study title

Pilot Study on Proteomics of Erythrocyte Proteins in Patients With Chronic Obstructive Pulmonary Disease Based on TMT Technology

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: May 17, 2022
Registry last updated: Mar 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed